Low-Density Lipoprotein Cholesterol and Dementia Risk: Integrating Mendelian Randomization and Target Trial Emulation Within the Heart–Brain Axis
Preprint
Abstract
Background: The heart–brain axis links cardiovascular and neurodegenerative disease through shared vascular and inflammatory mechanisms. Although low-density lipoprotein cholesterol ( LDL-C) is an established causal factor in atherosclerotic cardiovascular disease (ASCVD), its relationship with dementia remains uncertain, with midlife elevations associated with increased risk but late-life associations often appearing null or inverse. To address this cholesterol paradox, we integrated mendelian randomization (MR) with an active-comparator new-user target trial emulation. Methods: We applied a triangulated causal inference framework integrating two-sample MR with observational target trial emulation. Genetic variants associated with LDL-C were used as instrumental variables to evaluate Alzheimer’s disease (AD), Dementia with Lewy bodies (DLB), Frontotemporal dementia (FTD), and any dementia (AnyDem), with causal estimates derived using inverse-variance weighted models and sensitivity analyses for heterogeneity and pleiotropy. In parallel, an active-comparator new-user design compared statin versus ezetimibe initiation among adults aged ≥60 years using propensity score (PS) overlap weighting and Cox proportional hazards models to evaluate cardiovascular and dementia outcomes. Results: Genetically predicted LDL-C was associated with increased risk of DLB (OR 1.65, 95% CI 1.30–2.10; p<0.001), but not AD or AnyDem; FTD estimates were inconsistent. Sensitivity analyses suggested heterogeneity and possible pleiotropy for DLB. In the observational analysis (n=6,977), statin initiation was associated with higher risks of ASCVD (HR 1.26, 95% CI 1.11–1.45) and AnyDem (HR 1.66, 95% CI 1.16–2.38), although estimates attenuated after lipid adjustment and lagged analyses, suggesting residual confounding, treatment selection, and reverse causation in late-life observational associations. Conclusions: These findings suggest that LDL-C reflects accumulated vascular and metabolic risk rather than a direct causal driver of AD or overall dementia, although a subtype-specific association was observed for DLB. Late-life associations appeared influenced by timing, reverse causation, and treatment selection, warranting cautious interpretation.Keywords
Funding Information
- NIH (1R15HL172198)
- NIH (1R15HL173852)
This publication has 30 references indexed in Scilit:
- Deprescribing Cardiovascular Medications in Older Adults Living with FrailtyCJC Open, 2024
- Dementia prevention, intervention, and care: 2024 report of the Lancet standing CommissionThe Lancet, 2024
- Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studiesPharmacoepidemiology and Drug Safety, 2022
- The “All of Us” Research ProgramNew England Journal of Medicine, 2019
- Vascular Cognitive Impairment and DementiaJACC, 2019
- Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median EstimatorGenetic Epidemiology, 2016
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.American Journal of Epidemiology, 2016
- Statins, cognition, and dementia—systematic review and methodological commentaryNature Reviews Neurology, 2015
- Discovery and refinement of loci associated with lipid levelsNature Genetics, 2013
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart DiseaseJACC, 2012